异搏定对膀胱癌耐药性的逆转研究  

Verapamil Reversing Effects on Drug Resistance in Bladder Cancer

作　　者：周永建[1] 周鑫[1] 赵玉千[1] 韩志兴[1] 吴长利[2] 

机构地区：[1]首都医科大学附属北京天坛医院泌尿外科 [2]天津医科大学泌尿外科研究所

出　　处：《首都医科大学学报》2005年第3期339-341,共3页Journal of Capital Medical University

摘　　要：目的通过钙通道阻滞剂异搏定阻止抗癌药物从细胞内排出,探讨肿瘤细胞抗药性逆转的可能性。方法利用氮唑化合物(MTT)试验方法及高效液相色谱分析(HPLC)方法检测应用异搏定后肿瘤细胞对抗癌药物敏感性的改变。结果发现异搏定对膀胱癌敏感细胞(EJ)的生长无影响,而对膀胱癌耐药细胞(EJ-R)则随着异搏定质量浓度的增加,化疗药物的抗癌作用逐渐增强。结论异搏定通过阻滞钙通道,降低P-GP170排出抗癌药物的作用,使癌细胞内抗癌药物浓度得到保证,达到杀死肿瘤细胞的目的,即癌细胞抗药性得到逆转。Objective The hypothesis was under investigation that verapamil as a Calcium-channel antagonist, is introduced to prevent excretion of anticancer drugs from cells excerting reversing effects on drug resistance in bladder cancer. Methods MTT and HPLC method are applied to detect the alteration on the sensibility of cancer cells to anticancer drugs before and after introducing verapamil. Results Verapamil has no effect on the growth of bladder cancer-sensible cells(EJ). For the drug-resisted bladder cancer cells (EJ-R), effects of anti-cancer drugs are enhanced with the increasing concentration of verapamil. Conclusion Glucoprotein P-GP_ 170 on the membranes of bladder cancer cells can excrete anti-cancer drugs from the cells against concentration gradient. Verapamil blocks Calcium channels thereby reduce excretion of anti-cancer drugs by P-GP_ 170. By guaranteening the concentration of anti-cancer drugs in the cancer cells, drug resistance of cancer cells is reversed.

关 键 词：膀胱癌 多药耐药基因 耐药性 异搏定 药物治疗 

分 类 号：R737.14[医药卫生—肿瘤] R979.1[医药卫生—临床医学]